Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
3.800
+0.050 (1.33%)
Nov 25, 2025, 4:00 PM EST - Market closed
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
11.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 500.00K | - | - |
| Dec 31, 2021 | 500.00K | - | - |
| Dec 31, 2020 | 500.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IMNN News
- 12 days ago - Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 15 days ago - Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript - Seeking Alpha
- 15 days ago - IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer - GlobeNewsWire
- 15 days ago - IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer - GlobeNewsWire
- 18 days ago - IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment - GlobeNewsWire
- 19 days ago - IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025 - GlobeNewsWire
- 21 days ago - IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer - GlobeNewsWire